A Study of IBI302 in Patients With nAMD
NCT04820452
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
231
Enrollment
INDUSTRY
Sponsor class
Conditions
Neovascular Age-related Macular Degeneration
Interventions
BIOLOGICAL:
Low dose IBI302
BIOLOGICAL:
High dose IBI302
DRUG:
Aflibercept
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.